Dr. Heinzerling on the Development of New Treatments in Early-Stage Lung Cancer

Josh H. Heinzerling, MD
Published: Tuesday, Nov 21, 2017



Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses the development of new treatment regimens for patients with early-stage lung cancer.

There is a lot of work to do in earlier stages of disease, states Heinzerling. As CT screening is being adopted nationwide, more work will need to be done as this is going to shift the patient spectrum from stage IV disease to stage I, II, or III disease.

According to Heinzerling, the hope is there will be early-stage treatments and better cure rates.
 


Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses the development of new treatment regimens for patients with early-stage lung cancer.

There is a lot of work to do in earlier stages of disease, states Heinzerling. As CT screening is being adopted nationwide, more work will need to be done as this is going to shift the patient spectrum from stage IV disease to stage I, II, or III disease.

According to Heinzerling, the hope is there will be early-stage treatments and better cure rates.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x